Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Plus Chemotherapy in Adjuvant NSCLC
NCT05487391Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of iparomlimab, tuvonralimab in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Started Dec 2022; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05487391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487391.